Skip to main content
. 2018 Sep 20;13(9):e0204015. doi: 10.1371/journal.pone.0204015

Fig 1. Associations between the M-CHARTS score at baseline and 12 months after initiating intravitreal ranibizumab therapy.

Fig 1

The M-CHARTS score at baseline is significantly correlated with the M-CHARTS score 12 months after initiating intravitreal ranibizumab therapy for macular edema associated with branch retinal vein occlusion (r = 0.503, P = 0.003). The M-CHARTS score used in analyses was the higher score among the vertical and horizontal scores.